single-center study disease after marrow transplantation from HLA-matched siblings: a methylprednisolone for the prevention of acute graft-versus-host Tacrolimus (FK506) alone or in combination with methotrexate or

[1]  W. Bennett,et al.  Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. , 1994, Transplantation.

[2]  A. Nademanee,et al.  Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. , 1993, The New England journal of medicine.

[3]  H. Deeg,et al.  FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS , 1993, Transplantation.

[4]  M S Pepe,et al.  Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? , 1993, Statistics in medicine.

[5]  G. Milano,et al.  Severe interaction between methotrexate and a macrolide-like antibiotic. , 1993, Journal of the National Cancer Institute.

[6]  M. Pepe,et al.  Summarizing data on survival, relapse, and chronic graft‐versus‐host disease after bone marrow transplantation: motivation for and description of new methods , 1993, British journal of haematology.

[7]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[8]  G. Gores,et al.  Nephrotoxicity of FK 506 and cyclosporine when used as primary immunosuppression in liver transplant recipients. , 1993, Transplantation proceedings.

[9]  G. Klintmalm,et al.  Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. , 1993, Transplantation proceedings.

[10]  A. Demetris,et al.  FK 506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. , 1993, Transplantation proceedings.

[11]  D. V. van Thiel,et al.  Adverse effects of FK 506 overdosage after liver transplantation. , 1993, Transplantation proceedings.

[12]  Pepe,et al.  Marrow transplantation from unrelated donors for treatment of hematologic malignancies: effect of mismatching for one HLA locus. , 1993, Blood.

[13]  S. Takahara,et al.  FK506‐INDUCED KIDNEY TUBULAR CELL INJURY , 1992, Transplantation.

[14]  G. Kootstra,et al.  FK506‐INDUCED IMPAIRMENT OF GLUCOSE METABOLISM IN THE PRIMATE—STUDIES IN PANCREATIC TRANSPLANT RECIPIENTS AND IN NONTRANSPLANTED ANIMALS , 1992, Transplantation.

[15]  H. Deeg,et al.  Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. , 1992, Blood.

[16]  F. Dumont,et al.  The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin , 1992, The Journal of experimental medicine.

[17]  T. Starzl,et al.  Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. , 1992, Transplantation proceedings.

[18]  W. Jusko,et al.  Monitoring FK 506 concentrations in plasma and whole blood. , 1991, Transplantation proceedings.

[19]  J. Tai,et al.  Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. , 1991, Transplantation proceedings.

[20]  Anajane G. Smith,et al.  Polymorphism of HLA-DRw52-associated DRB1 genes as defined by sequence-specific oligonucleotide probe hybridization and sequencing. , 1991, Tissue antigens.

[21]  T. Starzl,et al.  PREVENTION OF GRAFT‐VERSUS‐HOST DISEASE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION IN RATS USING FK506 , 1991, Transplantation.

[22]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[23]  A. Demetris,et al.  FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. , 1991, Surgery.

[24]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity , 1991, Clinical pharmacology and therapeutics.

[25]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. , 1991, Blood.

[26]  S. Geisse,et al.  Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. , 1991, The New biologist.

[27]  S. Schreiber,et al.  The effect of the immunosuppressant FK‐506 on alternate pathways of T cell activation , 1991, European journal of immunology.

[28]  T. Starzl,et al.  Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. , 1991, Transplantation proceedings.

[29]  R. Storb,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. , 1990, Blood.

[30]  M. Bialer,et al.  Application of a variance-stabilizing transformation approach to linear regression of calibration lines. , 1990, Journal of pharmaceutical sciences.

[31]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.

[32]  M. Pepe,et al.  What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants ? , 1990 .

[33]  K. Sullivan,et al.  Value of day 100 screening studies for predicting the development of chronic graft-versus-host disease after allogeneic bone marrow transplantation. , 1990, Blood.

[34]  R Storb,et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. , 1989, Blood.

[35]  R. Zager,et al.  Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. , 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  H. Deeg,et al.  Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. , 1988, Blood.

[37]  K. O̸lgaard,et al.  The effect of cyclosporine A on the hepatic clearance rate of prednisone in isolated perfused livers of normal and uremic rats. , 1988, Transplantation proceedings.

[38]  K. Sullivan,et al.  Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. , 1987, Annals of internal medicine.

[39]  J. Klein,et al.  Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen , 1987 .

[40]  H. Deeg,et al.  Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. , 1986, Blood.

[41]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.

[42]  M. Namer,et al.  CLINICAL AND PHARMACOKINETIC EVIDENCE OF A LIFE-THREATENING INTERACTION BETWEEN METHOTREXATE AND KETOPROFEN , 1986, The Lancet.

[43]  R. Storb,et al.  Graft‐versus‐Host Disease in Dog and Man: The Seattle Experience , 1985, Immunological reviews.

[44]  H. Deeg,et al.  Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft‐versus‐host disease prophylaxis , 1985, British journal of haematology.

[45]  J. Säwe,et al.  HIGH DOSE METHYLPREDNISOLONE INCREASES PLASMA CYCLOSPORIN LEVELS IN RENAL TRANSPLANT RECIPIENTS , 1984, The Lancet.

[46]  L. Ost.  Effects of cyclosporin on prednisolone metabolism. , 1984, Lancet.

[47]  W. Jusko,et al.  Analysis of cortisol, methylprednisolone, and methylprednisolone hemisuccinate. Absence of effects of troleandomycin on ester hydrolysis. , 1984, Journal of chromatography.

[48]  K. Sullivan,et al.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.

[49]  R. Storb,et al.  Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.

[50]  W. Jusko,et al.  Corticosteroid analysis in biological fluids by high-performance liquid chromatography. , 1979, Journal of chromatography.